Antitussive side effects by duration, gender and age - a phase IV clinical study of FDA data

< 1 month:

1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
2. Hepatitis acute

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Abdominal pain upper
2. Abnormal behaviour
3. Acute myocardial infarction (acute heart attack)
4. Agitation (state of anxiety or nervous excitement)
5. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
6. Back pain
7. Cardiovascular disorder (heart diseases)
8. Chest x-ray abnormal
9. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
10. Confusion

female:

1. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
2. Alveolar proteinosis (alveolar proteinosis (pap) is a rare disease of the lungs in which abnormal accumulation of surfactant occurs within the alveoli)
3. Drug administration error
4. Asthenia (weakness)
5. Blood creatine phosphokinase increased
6. Acute myocardial infarction (acute heart attack)
7. Agitation (state of anxiety or nervous excitement)
8. Alanine aminotransferase increased
9. Cardiovascular disorder (heart diseases)
10. Chest x-ray abnormal

male:

1. Depressed level of consciousness
2. Alanine aminotransferase increased
3. Pneumonia
4. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
5. Generalised erythema (redness of the skin all over the body)
6. Abdominal pain upper
7. Abnormal behaviour
8. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
9. Diarrhoea haemorrhagic (bloody diarrhoea)
10. Disseminated intravascular coagulation (systemic activation of blood coagulation)

0-1:

n/a

2-9:

1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
2. Fear

10-19:

1. Depressed level of consciousness
2. Generalised erythema (redness of the skin all over the body)
3. Abnormal behaviour
4. Agitation (state of anxiety or nervous excitement)
5. Confusional state
6. Influenza

20-29:

1. Drug administration error
2. Disseminated intravascular coagulation (systemic activation of blood coagulation)
3. Drug resistance (reduction in effectiveness of a drug)

30-39:

1. Fall

40-49:

1. Alveolar proteinosis (alveolar proteinosis (pap) is a rare disease of the lungs in which abnormal accumulation of surfactant occurs within the alveoli)
2. Abdominal pain upper
3. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
4. Confusion
5. Diarrhoea haemorrhagic (bloody diarrhoea)
6. Pneumonia

50-59:

1. Alanine aminotransferase increased
2. Drug withdrawal syndrome neonatal (prenatal nas is caused by discontinuation of drugs taken by the pregnant mother)
3. Hepatitis acute
4. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
5. Pruritus generalised (generalized itching)

60+:

1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
2. Emotional disorder
3. Blood creatine phosphokinase increased
4. Acute myocardial infarction (acute heart attack)
5. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
6. Asthenia (weakness)
7. Cardiovascular disorder (heart diseases)